不过，康泰医学在研发方面取得了一定进展。公司称，长沙研发中心在上半年取得了全瓷义齿用氧化锆瓷块、血糖尿酸仪、血糖尿酸胆固醇仪、血糖试条、早孕试纸等9款产品的国内医疗器械注册证并上市销售，目前全瓷义齿用氧化锆瓷块已实现批量生产。此外，多款体外诊断产品已经完成了原型设计和初步测试，进入研发后期阶段，预计将于年内进入注册流程。The decline in performance in the first half of the year was attributed to a temporary destocking of downstream customers leading to a decrease in orders, as well as a high base from last year's performance. Currently, the mass production of zirconia ceramic blocks for all-ceramic dentures has been achieved, and multiple types of in vitro diagnostic products have entered the late stage of development, with an expected entry into the registration process this year. The company has already achieved market breakthroughs in multiple African countries and will continue to deepen its presence in the African market, increasing the deployment and marketing efforts of its products.
On September 12th, Caixin reported that medical device company Contec Medical Systems (300869.SZ) released its financial indicators for the first half of this year, which fell short of expectations. Not only did revenue fall drastically, but non-GAAP net profit also turned from profit to loss, with both gross margin and net margin seeing a significant year-on-year decrease. At the company's semi-annual earnings conference held today, Chairman Hu Kun explained the reasons for the decline in performance and outlined the company's future strategic planning.
During the conference, investors inquired about the poor performance of the company and whether there are any strategies to improve profitability and sales. Hu Kun stated that the decline in performance is mainly due to a decrease in orders caused by the destocking of downstream customers, as well as a high performance base resulting from a surge in domestic market demand in the first quarter of last year. The company plans to continue expanding both domestic and international markets, while focusing on maintaining market share and striving to enhance the company's sustainable profitability.
However, Contec Medical Systems has made progress in research and development. The company announced that its R&D center in Changsha obtained domestic medical device registration certificates for 9 products, including zirconia ceramic blocks for all-ceramic dentures, blood glucose and uric acid meters, blood glucose, uric acid, and cholesterol meters, blood glucose test strips, and early pregnancy test strips, which are now on the market. Mass production of zirconia ceramic blocks for all-ceramic dentures has already been achieved. In addition, multiple types of in vitro diagnostic products have completed prototype design and preliminary testing, entering the late stage of development, with an expected entry into the registration process this year.
The company's secretary, Zheng Min, stated that the company plans to increase research and development investment in the fields of elderly care and home medical care. The focus of research and development will be on developing smart medical testing devices, client software, and Internet of Things terminals that cater to the health needs of the elderly, with a particular emphasis on remote medical services based on big data and Internet of Things technologies. In terms of market expansion, company General Manager Yang Zhishan stated that the company will segment the sales team and market, increase the development efforts in key markets, and achieve greater market coverage. In terms of overseas markets, the company will actively participate in the Belt and Road Initiative, especially by localizing overseas markets, expanding cross-border e-commerce channels, and participating in exhibitions to develop business in Africa. Currently, the company has achieved market breakthroughs in multiple African countries and will continue to deepen its presence in the African market, increasing the deployment and marketing efforts of its products.
At the earnings conference, Contec Medical Systems' long-term low stock price also raised concerns among some investors. Some investors also inquired about the company's plans for convertible bonds and suggested lowering the conversion price of convertible bonds to take advantage of the market situation. In response, the company explained that stock prices are influenced by macroeconomic conditions, market liquidity, and investor sentiment, and reiterated its commitment to enhancing the market value of the company by solidifying its core business and improving profitability. Regarding convertible bonds, the company stated that all the raised funds from the convertible bonds have already been used for their intended projects, and the company will decide on subsequent plans and consider lowering the conversion price based on actual conditions and strategic needs.
Please note that the company's forward-looking statements are subjective, and actual results could be materially different from those expressed or implied by these statements, which are based on the current beliefs, expectations, and assumptions of management.
This translation is an accurate and complete representation of the original text. However, there may be slight variations in the formatting and punctuation.
